249 related articles for article (PubMed ID: 31291624)
1. A Potential Mechanism of Cardio-Renal Protection with Sodium-Glucose Cotransporter 2 Inhibitors: Amelioration of Renal Congestion.
Kuriyama S
Kidney Blood Press Res; 2019; 44(4):449-456. PubMed ID: 31291624
[TBL] [Abstract][Full Text] [Related]
2. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A
J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
[TBL] [Abstract][Full Text] [Related]
3. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibition and kidney protection.
Nespoux J; Vallon V
Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
[TBL] [Abstract][Full Text] [Related]
5. Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction.
Wakisaka M; Kamouchi M; Kitazono T
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31726765
[TBL] [Abstract][Full Text] [Related]
6. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
Hesp AC; Schaub JA; Prasad PV; Vallon V; Laverman GD; Bjornstad P; van Raalte DH
Kidney Int; 2020 Sep; 98(3):579-589. PubMed ID: 32739206
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells.
Maki T; Maeno S; Maeda Y; Yamato M; Sonoda N; Ogawa Y; Wakisaka M; Inoguchi T
Sci Rep; 2019 Mar; 9(1):4703. PubMed ID: 30886225
[TBL] [Abstract][Full Text] [Related]
8. SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
Georgianos PI; Divani M; Eleftheriadis T; Mertens PR; Liakopoulos V
Curr Med Chem; 2019; 26(29):5564-5578. PubMed ID: 29792136
[TBL] [Abstract][Full Text] [Related]
9. Renal intrinsic cells remodeling in diabetic kidney disease and the regulatory effects of SGLT2 Inhibitors.
Guo W; Li H; Li Y; Kong W
Biomed Pharmacother; 2023 Sep; 165():115025. PubMed ID: 37385209
[TBL] [Abstract][Full Text] [Related]
10. Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease.
Gan T; Song Y; Guo F; Qin G
Mol Biol Rep; 2022 Nov; 49(11):10915-10924. PubMed ID: 36002651
[TBL] [Abstract][Full Text] [Related]
11. Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes.
van Raalte DH; Bjornstad P
Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i24-i32. PubMed ID: 32003832
[TBL] [Abstract][Full Text] [Related]
12. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms.
Kashihara N; Kidokoro K; Kanda E
Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):112-118. PubMed ID: 31725011
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose cotransporter-2 inhibitors for diabetic kidney disease: Targeting Warburg effects in proximal tubular cells.
Morita M; Kanasaki K
Diabetes Metab; 2020 Oct; 46(5):353-361. PubMed ID: 32891754
[TBL] [Abstract][Full Text] [Related]
14. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
[TBL] [Abstract][Full Text] [Related]
15. Protection of the kidney with sodium-glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials.
Kuriyama S
Clin Exp Nephrol; 2019 Mar; 23(3):304-312. PubMed ID: 30478731
[TBL] [Abstract][Full Text] [Related]
16. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
Thomas MC; Cherney DZI
Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
Scheen AJ
Expert Opin Drug Saf; 2020 Mar; 19(3):243-256. PubMed ID: 32083962
[No Abstract] [Full Text] [Related]
18. Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation.
Sano M
Ther Adv Cardiovasc Dis; 2020; 14():1753944720939383. PubMed ID: 32715944
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease.
Shaffner J; Chen B; Malhotra DK; Dworkin LD; Gong R
Front Endocrinol (Lausanne); 2021; 12():749010. PubMed ID: 34790170
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease.
Górriz JL; Navarro-González JF; Ortiz A; Vergara A; Nuñez J; Jacobs-Cachá C; Martínez-Castelao A; Soler MJ
Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i13-i23. PubMed ID: 32003834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
